NGNE vs. EOLS, AVDL, AVXL, PHVS, CDMO, QURE, ABCL, CMRX, PRAX, and BCAX
Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Anavex Life Sciences (AVXL), Pharvaris (PHVS), Avid Bioservices (CDMO), uniQure (QURE), AbCellera Biologics (ABCL), Chimerix (CMRX), Praxis Precision Medicines (PRAX), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry.
Neurogene vs.
Evolus (NASDAQ:EOLS) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.
Neurogene has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.
Evolus received 331 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 72.97% of users gave Evolus an outperform vote.
In the previous week, Neurogene had 13 more articles in the media than Evolus. MarketBeat recorded 22 mentions for Neurogene and 9 mentions for Evolus. Neurogene's average media sentiment score of 0.74 beat Evolus' score of 0.25 indicating that Neurogene is being referred to more favorably in the news media.
Neurogene has a net margin of 0.00% compared to Evolus' net margin of -22.33%. Neurogene's return on equity of -32.81% beat Evolus' return on equity.
Evolus presently has a consensus price target of $24.67, indicating a potential upside of 101.53%. Neurogene has a consensus price target of $59.80, indicating a potential upside of 290.08%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Evolus.
90.7% of Evolus shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 6.1% of Evolus shares are held by company insiders. Comparatively, 9.9% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Evolus has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Summary
Neurogene beats Evolus on 13 of the 19 factors compared between the two stocks.
Get Neurogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurogene Competitors List
Related Companies and Tools
This page (NASDAQ:NGNE) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy NGNE Stock Free NGNE Stock Alerts